Takeda Completes Share Repurchase Program in May 2025

Takeda Pharmaceutical Company ( (TAK) ) has issued an announcement.

Takeda Pharmaceutical Company announced the completion of its share repurchase program, which was conducted from February 17, 2025, to May 31, 2025. The company successfully repurchased 23,367,100 shares, amounting to approximately 99.96% of the planned 28,500,000 shares, with a total expenditure of 99,955,865,500 JPY. This strategic move is likely to impact the company’s financial structure and shareholder value positively.

The most recent analyst rating on (TAK) stock is a Hold with a $13.40 price target. To see the full list of analyst forecasts on Takeda Pharmaceutical Company stock, see the TAK Stock Forecast page.

Spark’s Take on TAK Stock

According to Spark, TipRanks’ AI Analyst, TAK is a Outperform.

Takeda Pharmaceutical Company demonstrates strong financial performance, driven by consistent revenue and profit growth, a solid balance sheet, and effective cash flow management. While the company’s technical indicators show moderate bullish momentum, the high P/E ratio raises valuation concerns. The mixed earnings call highlights both promising product launches and challenges from generic competition. Overall, Takeda’s strong fundamentals and promising pipeline are somewhat tempered by valuation and competitive pressures, resulting in an overall stock score of 71.

To see Spark’s full report on TAK stock, click here.

More about Takeda Pharmaceutical Company

Takeda Pharmaceutical Company Limited is a global pharmaceutical company based in Japan, primarily involved in the research, development, and marketing of pharmaceutical products. The company focuses on providing innovative medicines in areas such as oncology, gastroenterology, neuroscience, and rare diseases, aiming to improve patient outcomes worldwide.

Average Trading Volume: 2,106,012

Technical Sentiment Signal: Buy

Current Market Cap: $48.04B

For detailed information about TAK stock, go to TipRanks’ Stock Analysis page.